S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Citizens JMP lowered its price target on OrthoPediatrics Corp. (NASDAQ:KIDS) to $35.00 from $50.00 on Friday, while maintaining a Market Outperform rating following the company’s second-quarter 2025 results. According to InvestingPro data, the company currently has a market capitalization of $481 million and maintains strong liquidity with a current ratio of 6.66.
OrthoPediatrics reported quarterly revenue of $61.1 million, representing 16% year-over-year growth, which fell short of the consensus estimate of $62.5 million despite setting a company record for quarterly sales.
The pediatric orthopedic device maker posted adjusted EBITDA of $4.1 million, a 58% increase year-over-year, but slightly below analyst expectations of $4.3 million.
Citizens JMP noted that despite a temporary slowdown in limb deformity procedures, OrthoPediatrics continues to gain market share across all its key segments, supporting the firm’s maintained Market Outperform rating.
The company largely reiterated its full-year guidance, with a slight upward adjustment to its revenue forecast, which Citizens JMP cited as evidence that the fundamental business outlook remains solid.
In other recent news, OrthoPediatrics Corporation reported its second-quarter 2025 financial results, showcasing a revenue of $61.1 million. This figure marks a 16% increase compared to the previous year, although it fell slightly short of the $61.5 million expected by BTIG and consensus estimates. The company’s Trauma & Deformity sales increased to $41.7 million, representing a 10.3% year-over-year growth, while Scoliosis sales rose significantly by 35.4% to $18.5 million. However, the Sports Medicine/Other segment experienced a decline, with sales dropping 32.9% to $0.9 million. On the earnings side, OrthoPediatrics reported an earnings per share (EPS) of -$0.11, which was a notable improvement over the forecasted -$0.29. Despite this earnings beat, BTIG adjusted its price target for the company to $39.00 from $40.00, while maintaining a Buy rating. These recent developments provide investors with a mixed picture of the company’s financial performance and market reception.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.